Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $17000.0.

  • Biofrontera's Depreciation & Amortization (CF) fell 1500.0% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $94000.0, marking a year-over-year increase of 1325.3%. This contributed to the annual value of $600000.0 for FY2024, which is 0.0% changed from last year.
  • Biofrontera's Depreciation & Amortization (CF) amounted to $17000.0 in Q3 2025, which was down 1500.0% from $22000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Depreciation & Amortization (CF) registered a high of $33000.0 during Q1 2021, and its lowest value of $17000.0 during Q3 2025.
  • For the 5-year period, Biofrontera's Depreciation & Amortization (CF) averaged around $24105.3, with its median value being $22000.0 (2021).
  • As far as peak fluctuations go, Biofrontera's Depreciation & Amortization (CF) crashed by 2121.21% in 2022, and later soared by 4285.71% in 2024.
  • Quarter analysis of 5 years shows Biofrontera's Depreciation & Amortization (CF) stood at $22000.0 in 2021, then fell by 4.55% to $21000.0 in 2022, then changed by 0.0% to $21000.0 in 2023, then soared by 42.86% to $30000.0 in 2024, then plummeted by 43.33% to $17000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $17000.0 in Q3 2025, compared to $22000.0 in Q2 2025 and $25000.0 in Q1 2025.